Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

NCT03157128 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03157128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03157128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 2, 2017
Completion date
February 28, 2027
Enrollment
857 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

any solid tumor, colon cancer, medullary thyroid cancer, non-small cell lung cancer